Alain Mina, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10 Room 6N119
- Bethesda, MD 20892
My research focuses on identifying signaling pathways that promote leukemogenesis in myeloid malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia as well as developing targeted therapies that could be brought forth into clinical trials. Goal would be to move towards a chemotherapy-free targeted treatment strategy. Other modalities to achieve that goal would be the development of chimeric antigen receptor (CAR) T cells (targeting myeloid cell antigens such as CLL-1, CD123, CD33, etc.), bispecific T cell engagers (BiTE) and immune checkpoint blockade.
Areas of Expertise
1) Cell Therapy 2) Stem Cell Transplant 3) Myeloid Malignancies 4) Myelodysplastic Syndromes (MDS) 5) Acute Myelogenous Leukemia (AML) 6) Drug Development
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
My research efforts primarily focus on:
- Understanding the role of aberrant signal transduction pathways in the development of myeloid neoplasms.
- Defining molecular targets for the treatment of leukemia.
- Preclinical MDS/AML models design
- Preclinical drug development and early phase trials design.
- Translating adult stem cell laboratory research findings into clinical interventions with focus on myeloid malignancies.
- Translating the success of cellular therapies in B-cell lymphomas into the realm of myeloid neoplasms.